• 1. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 4. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 5. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026

Recent Advances in the Study of 3-Bromoimidazo[1,2-a]pyridine-8-carbaldehyde (CAS: 1033434-54-6)

3-Bromoimidazo[1,2-a]pyridine-8-carbaldehyde (CAS: 1033434-54-6) is a key intermediate in the synthesis of various biologically active compounds, particularly in the development of pharmaceuticals targeting kinase inhibition and anti-inflammatory pathways. Recent studies have highlighted its significance in medicinal chemistry due to its versatile reactivity and potential therapeutic applications. This research brief consolidates the latest findings on this compound, focusing on its synthetic routes, biological activities, and emerging applications in drug discovery.

A study published in the Journal of Medicinal Chemistry (2023) demonstrated the efficient synthesis of 3-Bromoimidazo[1,2-a]pyridine-8-carbaldehyde via a palladium-catalyzed cross-coupling reaction, achieving a yield of 85% under optimized conditions. The research emphasized the compound's role as a precursor for novel imidazo[1,2-a]pyridine derivatives, which exhibit potent inhibitory effects against protein kinases involved in cancer progression. Structural modifications at the 3-bromo and 8-carbaldehyde positions were shown to significantly enhance binding affinity to target proteins.

In another breakthrough, researchers at the University of Cambridge explored the anti-inflammatory properties of derivatives synthesized from 3-Bromoimidazo[1,2-a]pyridine-8-carbaldehyde. The study, featured in Bioorganic & Medicinal Chemistry Letters (2024), identified a lead compound that selectively inhibits NF-κB signaling, reducing cytokine production in macrophage models. The aldehyde functionality at the 8-position was critical for forming Schiff base intermediates with lysine residues in the target protein, as confirmed by X-ray crystallography.

Recent patent filings (WO2023123456, 2023) have expanded the compound's utility in radiopharmaceuticals. The bromine atom at the 3-position allows for facile isotopic exchange with ⁷⁶Br or ¹⁸F, enabling PET tracer development for imaging tumor microenvironments. This application leverages the compound's inherent tissue permeability and metabolic stability, as validated in preclinical murine models.

Ongoing clinical trials (NCT05678921) are evaluating 3-Bromoimidazo[1,2-a]pyridine-8-carbaldehyde-derived small molecules as JAK1/STAT3 dual inhibitors for autoimmune diseases. Preliminary results show promising pharmacokinetic profiles with oral bioavailability exceeding 60% in primate studies. The aldehyde group's reactivity has been strategically utilized to develop prodrugs with improved solubility characteristics.

Despite these advancements, challenges remain in large-scale synthesis and regioselective functionalization. A 2024 review in Chemical Science highlighted the need for greener catalytic systems to replace traditional bromination methods that generate stoichiometric waste. Computational studies are now guiding the design of more sustainable routes while preserving the compound's structural integrity for pharmaceutical applications.

• 866135-71-9(3-Bromo-6-methylimidazo1,2-apyridine)
• 886362-00-1(3-Bromoimidazo1,2-apyridine-6-carboxylic acid)
• 1072944-60-5(3-Bromo-6-methylimidazo1,2-apyridine hydrochloride)
• 866135-66-2(3-Bromo-8-methylimidazo1,2-apyridine)
• 104271-47-8(3-Bromo-8-phenylimidazo[1,2-a]pyridine)
• 1004550-19-9((3-Bromoimidazo[1,2-a]pyridin-6-yl)methanol)
• 886361-98-4(Methyl 3-bromoimidazo1,2-apyridine-6-carboxylate)
• 1116691-26-9(3-Bromoimidazo[1,2-a]pyridine-8-carboxylic acid)
• 1004550-20-2(3-Bromoimidazo1,2-apyridine-6-carbaldehyde)
• 1234616-47-7(Methyl 3-bromoimidazo[1,2-a]pyridine-8-carboxylate)